Know Cancer

or
forgot password

A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen


Phase 2
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen


Inclusion Criteria:



- Advanced, EGFR-positive NSCLC

- ECOG Performance Status 0, 1 or 2

- Measurable disease

Exclusion Criteria:

- Known CNS metastasis

- Pre-existing autoimmune or antibody mediated disease

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-Free Survival

Outcome Time Frame:

50Events

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A8501006

NCT ID:

NCT00321815

Start Date:

August 2006

Completion Date:

June 2010

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • advanced carcinoma non-small cell lung EGFR positive Erlotinib Tarceva PF-3512676 Phase II immunotherapy immune modulator
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Pfizer Investigational Site Birmingham, Alabama  35205
Pfizer Investigational Site Blendora, California  91740
Pfizer Investigational Site Crestview Hills, Kentucky  41017
Pfizer Investigational Site Cincinnait, Ohio  45236
Pfizer Investigational Site Bronx, New York  10461
Pfizer Investigational Site Houston, Texas  77030
Pfizer Investigational Site Clearwater, Florida  33761
Pfizer Investigational Site Carmel, Indiana  46032
Pfizer Investigational Site Cedar Rapids, Iowa  52403
Pfizer Investigational Site Columbia, Missouri  65201
Pfizer Investigational Site Kingston, Pennsylvania  18704-5535
Pfizer Investigational Site Farmington, Connecticut  06030-3805
Pfizer Investigational Site Bristol, Tennessee  37620
Pfizer Investigational Site Livingston, New Jersey  07039